Matthew Martini, MD
Interventional Cardiology · Pleasant Prairie, WINPI 1184087462
Payments from drug & device makers
Across 80 payments — averaging $56.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Boston Scientific$554
- Abbott$543
- E.r. Squibb & Sons, L.L.C.$287
- Abiomed$224
- Medtronic$164
- plus $758 from 11 others
What the payments were for
- Travel & lodging$1,65436%
- Food & beverage$2,32851%
- Education$56312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 17 | $2,014 |
| Boston Scientific | 7 | $554 |
| Abbott | 9 | $543 |
| E.r. Squibb & Sons, L.L.C. | 14 | $287 |
| Abiomed | 9 | $224 |
| Medtronic | 1 | $164 |
| Heartflow, Inc. | 7 | $158 |
| AstraZeneca | 3 | $157 |
| Inari Medical, Inc. | 1 | $107 |
| Novo Nordisk | 4 | $86 |
| Chiesi USA, Inc. | 1 | $72 |
| Novartis | 2 | $50 |
| Penumbra, Inc. | 1 | $48 |
| Recor Medical Inc | 1 | $25 |
| Biosense Webster, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $16 |
| Lilly USA, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,545 in reported general payments places this provider in the 45th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $19,057 |
| Metoprolol Succinate | 50 | $782 |
| Losartan Potassium | 25 | $264 |
| Irbesartan | 24 | $227 |
| Rosuvastatin Calcium | 23 | $222 |
| ClopidogrelClopidogrel Bisulfate | 21 | $202 |
| Amlodipine Besylate | 20 | $170 |
| Warfarin Sodium | 17 | $152 |
| Atorvastatin Calcium | 14 | $152 |
| Carvedilol | 11 | $150 |
| Spironolactone | 12 | $101 |
| Furosemide | 14 | $28 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Pleasant Prairie
- Tanvir BajwaMilwaukee$3M
- Suhail AllaqabandMilwaukee$1.5M
- Amish RavalMadison$921K
- German LarrainWausau$820K
- Simil GalaGreen Bay$588K
- Michael SalingerMilwaukee$356K
- Kurt JacobsonMadison$226K
- Michael RosenbergManitowoc$203K
- Arun KalyanasundaramMarshfield$201K
- Michael CinquegraniMilwaukee$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.